Table 2.
Univariate cox regression analysis of factors associated with mortality risk in STEMI patients undergoing PPCI
| Characteristics | HR | CI% | Z-score | P-value |
|---|---|---|---|---|
| Male vs Female | 0.549 | 0.247–1.223 | -1.468 | 0.142 |
| Age, per year | 1.062 | 1.026–1.099 | 3.411 | 0.001 |
| Obesity | 0.385 | 0.133–1.114 | -1.76 | 0.078 |
| Current smoker | 0.439 | 0.201–0.959 | -2.064 | 0.039 |
| Current drinker | 0.523 | 0.124–2.209 | -0.882 | 0.378 |
| Stroke | 2.45 | 1.035–5.8 | 2.038 | 0.042 |
| Diabetes | 0.92 | 0.389–2.175 | -0.19 | 0.849 |
| Renal insufficiency | 3.775 | 1.751–8.136 | 3.39 | 0.001 |
| Hypertension | 1.625 | 0.73–3.618 | 1.188 | 0.235 |
| Hyperlipidemia | 0.543 | 0.229–1.284 | -1.391 | 0.164 |
| Atrial fibrillation | 2.818 | 1.067–7.447 | 2.09 | 0.037 |
| Heart valve disease | 1.246 | 0.471–3.294 | 0.443 | 0.657 |
| Cardiomyopathy | 1.705 | 0.4–7.268 | 0.721 | 0.471 |
| Anemia | 0.849 | 0.293–2.458 | -0.302 | 0.763 |
| Killip Classification, II-VI vs I | 2.05 | 1.529–2.747 | 4.8 | < 0.001 |
| NT-proBNP/100 | 1.009 | 1.005–1.013 | 4.816 | < 0.001 |
| TnT | 0.97 | 0.872–1.079 | -0.561 | 0.575 |
| LVEF | 0.921 | 0.887–0.956 | -4.306 | < 0.001 |
| Beta-blocker | 0.275 | 0.12–0.629 | -3.06 | 0.002 |
| ACEI/ARB/ARNI | 0.16 | 0.075–0.342 | -4.736 | < 0.001 |
| Diuretics | 0.817 | 0.384–1.738 | -0.525 | 0.6 |
| Surgical approach, Radial artery vs Femoral artery | 2.344 | 0.81–6.783 | 1.571 | 0.116 |
| Main diseased vessel, others vs LAD | 0.808 | 0.537–1.217 | -1.02 | 0.308 |
| Stenosis degree, 100% vs 90–99% | 1.034 | 0.453–2.362 | 0.079 | 0.937 |
| Preoperative TIMI, 1–3 vs 0 | 0.906 | 0.62–1.326 | -0.507 | 0.612 |
| Implanted stents, 1–3 vs 0 | 0.619 | 0.311–1.232 | -1.366 | 0.172 |
| Infect | 0.976 | 0.337–2.826 | -0.045 | 0.964 |
| Shock | 3.655 | 1.384–9.657 | 2.615 | 0.009 |
| Bleeding | 0 | 0-Inf | -0.004 | 0.997 |
| New heart failure in hospital | 2.605 | 0.617–11 | 1.303 | 0.193 |
Bold represent significant values (p < 0.05)
Abbreviations: STEMI ST-segment elevation myocardial infarction, PPCI primary percutaneous coronary intervention, P-value Probability value, HR Hazard Ratio, CI Confidence Interval, N/n number, NT-proBNP:N-terminal pro-B type natriureti peptide, TnT Troponin T, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, ARNI angiotensin receptor-enkephalase inhibitors, TIMI thrombolysis in myocardial infarction